Yasunobu Matsumoto Selected Research

Vaccines

3/2023	Influence of BoLA-DRB3 Polymorphism and Bovine Leukemia Virus (BLV) Infection on Dairy Cattle Productivity.
12/2009	Malaria ookinete surface protein-based vaccination via the intranasal route completely blocks parasite transmission in both passive and active vaccination regimens in a rodent model of malaria infection.
4/2009	Oral immunogenicity and protective efficacy in mice of transgenic rice plants producing a vaccine candidate antigen (As16) of Ascaris suum fused with cholera toxin B subunit.
1/2009	Mucosal vaccination approach against mosquito-borne Japanese encephalitis virus.
11/2005	Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum.
11/2004	Recombinant Ascaris 16-Kilodalton protein-induced protection against Ascaris suum larval migration after intranasal vaccination in pigs.
9/2003	Mice intranasally immunized with a recombinant 16-kilodalton antigen from roundworm Ascaris parasites are protected against larval migration of Ascaris suum.
7/2003	Serum antibodies induced by intranasal immunization of mice with Plasmodium vivax Pvs25 co-administered with cholera toxin completely block parasite transmission to mosquitoes.
4/2003	Recombinant bovine herpesvirus-1 expressing p23 protein of Cryptosporidium parvum induces neutralizing antibodies in rabbits.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yasunobu Matsumoto Research Topics

Disease

6	Infections 03/2023 - 03/2002
3	Deltaretrovirus Infections (BLV Infection) 03/2023 - 01/2021
3	Lymphoma (Lymphomas) 03/2023 - 01/2021
3	Leishmaniasis 03/2010 - 07/2002
3	Malaria 12/2009 - 07/2003
2	Disease Progression 01/2022 - 07/2002
2	Melanoma (Melanoma, Malignant) 01/2011 - 08/2010
2	Parasitic Diseases (Parasitic Disease) 04/2009 - 04/2003
2	Ascariasis 11/2004 - 09/2003
1	Enzootic Bovine Leukosis (Bovine Leukosis) 03/2023
1	Breast Neoplasms (Breast Cancer) 01/2022
1	Tick Bites 10/2014
1	Inflammation (Inflammations) 10/2014
1	Tick Infestations 03/2012
1	Experimental Melanoma 01/2011
1	Atrophy 08/2010
1	Necrosis 06/2010
1	Body Weight (Weight, Body) 04/2010
1	Weight Loss (Weight Reduction) 04/2010
1	Hypersensitivity (Allergy) 01/2009
1	Rabies (Hydrophobia) 01/2008
1	Hepatitis 08/2007
1	Chagas Disease (American Trypanosomiasis) 11/2005
1	Mosquito-Borne Diseases 11/2005
1	Cryptosporidiosis 04/2003

Drug/Important Bio-Agent (IBA)

9	VaccinesIBA 03/2023 - 04/2003
7	AntigensIBA 04/2021 - 12/2002
4	BoLA-DRB3 antigenIBA 03/2023 - 01/2021
3	Proteins (Proteins, Gene)FDA Link 03/2010 - 03/2002
3	Membrane Proteins (Integral Membrane Proteins)IBA 12/2009 - 04/2003
2	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 04/2021
2	Amino Acids FDA Link 04/2021 - 09/2003
2	Interleukin-12 (IL 12)IBA 01/2011 - 06/2008
2	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2011 - 08/2010
2	Dexamethasone (Maxidex)FDA LinkGeneric 08/2010 - 04/2010
1	Deltaretrovirus AntibodiesIBA 01/2022
1	EnzymesIBA 01/2022
1	ImmunosorbentsIBA 01/2022
1	LigandsIBA 10/2014
1	Serine Proteases (Serine Protease)IBA 03/2012
1	Immunologic Adjuvants (Immunologic Adjuvant)IBA 01/2011
1	BromidesIBA 01/2011
1	NF-kappa B (NF-kB)IBA 06/2010
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 06/2010
1	Malaria VaccinesIBA 12/2009
1	Complement System Proteins (Complement)IBA 12/2009
1	Bacterial ToxinsIBA 01/2009
1	CytokinesIBA 06/2008
1	InterferonsIBA 06/2008
1	RNA (Ribonucleic Acid)IBA 08/2007
1	AntibodiesIBA 08/2007
1	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 11/2005
1	Cholera ToxinIBA 07/2003
1	Immune Sera (Antisera)IBA 07/2003
1	Pyridinolcarbamate (P23)IBA 04/2003
1	5-bromo-4-chloro-3-indolyl beta-galactoside (X-gal)IBA 04/2003
1	Receptors for Activated C KinaseIBA 07/2002
1	Complementary DNA (cDNA)IBA 07/2002

Therapy/Procedure

1	Oral Administration 01/2011
1	Therapeutics 01/2011